Previous 10 | Next 10 |
2023-10-25 11:55:27 ET Ideaya Biosciences (NASDAQ: IDYA) stock is falling in Wednesday's trading. The company's share price was down 8.1% as of 11 a.m. ET, according to data from S&P Global Market Intelligence . Ideaya Biosciences published a press release after the mark...
2023-10-25 10:00:16 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...
2023-10-25 08:44:46 ET Losers: Sonnet BioTherapeutics Holdings ( SONN ) -35% announces pricing of $4.55 Million underwritten public offering . Alphatec Holdings ( ATEC ) -18% prices $150M stock offering at $10.50 per share. MAIA Biotechnology ( MAIA ...
2023-10-25 05:35:18 ET More on IDEAYA Biosciences IDEAYA's Triple Threat: Melanoma, Money, And Momentum Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead IDEAYA announces proposed public offering of common stock and pre-funded warrants F...
2023-10-24 17:37:02 ET Gainers: Vitru ( VTRU ) +15% . Scholar Rock Holding ( SRRK ) +7% . LianBio ( LIAN ) +5% . 908 Devices ( MASS ) +5% . Microsoft Corporation ( MSFT ) +4% . Losers: Forbion European A...
2023-10-24 16:31:16 ET More on IDEAYA Biosciences IDEAYA's Triple Threat: Melanoma, Money, And Momentum Ideaya Biosciences: Eye Cancer Therapy Drives Gains - More Upside Ahead Tango Therapeutics stock plunges amid Amgen PRMT5 drug data (update) Ideaya Bio pic...
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $1...
2023-10-23 17:42:52 ET Gainers: Redfin ( RDFN ) +15% . Agilysys ( AGYS ) +11% . Medpace Holdings ( MEDP ) +5% . HomeStreet ( HMST ) +5% . IDEAYA Biosciences ( IDYA ) +5% . Losers: CareDx ( CDNA ) -8% . A...
IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline PR Newswire 60% confirmed ORR% by RECIST 1.1 in HLA-A2(+) in 1L MU...
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma PR Newswire Proffered paper oral presentation at ESMO 2023 scheduled for Monday, October...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study PR Newswire 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients...